INTRODUCTION

A tic is an observable, sudden, rapid, repetitive, and non-rhythmic movement that can occur in any part of the human body. Rapid, repetitive, and non-rhythmic vocalizations are also classified as tics. The onset of tics usually occurs when patients are between 3 and 8 years of age, and its symptoms peak between 10 and 12 years of age. Tic symptoms progressively improve as patients proceed through puberty, and 60–80% of patients show a complete or significant absence of these symptoms by adulthood [1,2].

The diagnostic criteria recently published in the diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) suggest that patients with tic symptoms that persist for ≥1 year can be diagnosed with persistent motor or vocal tic disorder or Tourette’s disorder (TD). Although the main therapies for these disorders are behavioral and pharmacological in nature, evaluating the effectiveness of treatments is extremely difficult because tic symptoms wax and wane.

Tics have traditionally been considered to be involuntary hyperkinetic movements. However, most TD patients report experiencing an unpleasant and distressing somatosensory event called the premonitory urge immediately before a tic occurs [3].

Several studies have been performed to identify the clinical characteristics of premonitory urges in order to target these urges therapeutically. In this review article, we will provide a comprehensive summary of the findings of previous studies assessing the clinical characteristics of the premonitory urge, the association between the premonitory urge and comorbid psychiatric disorders in TD patients, and therapeutic utilization of the premonitory urge.

CLINICAL CHARACTERISTICS OF THE PREMONITORY URGE

Previous studies have defined the premonitory urge as an occurrence of localized muscle tension. However, few TD patients experience this symptom [4,5]. In contrast, if the premonitory urge is re-defined as an uncomfortable somatic sensation occurring before tics, over 90% of TD patients would...
be classified as having these urges [3,4]. Although earlier studies reported a greater frequency of premonitory urges in males compared to females [3], follow-up studies showed no clear differences based on gender [6-8]. In addition, the association between intelligence quotient (IQ) and the severity of the premonitory urge has not been consistently observed in different studies. Woods et al. [9] reported that there was no relationship between IQ and the severity of premonitory urges, while Reese et al. [8] suggested that an increased severity of premonitory urges was correlated with high IQ.

The mean age of pediatric patients reporting symptoms of premonitory urges is 10 years, approximately 3 years after the onset of tics [3]. Although there is no clear explanation for this delay in symptom manifestation, it has been proposed that limitations in the cognitive abilities of pediatric patients might prevent them from correctly expressing or reporting the symptoms of premonitory urges [9]. This hypothesis is further supported by the outcomes of previous studies showing that pediatric patients who are less than 10 years old rarely report having premonitory urges [3], and that premonitory urges are reported more frequently in TD patients as they age [10].

Premonitory urges can manifest anywhere in the human body, and the symptoms can be felt systemically or can be localized. However, the symptoms are frequently experienced in the face, neck, shoulders, arms, palms, or midline abdomen [3,11,12]. A previous study described the premonitory urge as the sensation of an extensive amount of energy in the muscle, joint, or sometimes the skin of the patient. The premonitory urge has also been described as a feeling similar to hiccups, strong or intense feelings, pressure inside the brain or body, or itching [3]. Other studies have described it as an urge to move. Some patients have described this phenomenon as tension, a tickling sensation, pruritus, a feeling that something is just not right, a sense of incompleteness, an impulse to manifest tics, or a feeling that they will be satisfied after the expression of tics [12,13]. Among these descriptions, the “just right” phenomenon is expressed in terms of all sensory perceptions, including visual, tactile, and auditory sensations. The tic appears repeatedly until the patient feels that “something is complete” [13].

In order to assess the characteristics of premonitory urges, Woods et al. [9] developed the premonitory urge for tics scale (PUTS), and Sutherland Owens et al. [7] developed the University of Sao Paulo Sensory Phenomena Scale. McGuire et al. [14] recently developed the individualized PUTS (I-PUTS), which is quite different from the traditional PUTS in multiple aspects. Unlike the PUTS, which is a self-reporting scale assessing general symptoms of premonitory urges, the I-PUTS is a clinician-rated scale that is used to perform a multi-dimensional assessment of premonitory urges, including the frequency, severity, and specific location of the symptoms. Tics and PMUs experienced by the patient in the past week are simultaneously evaluated. Thus, the I-PUTS is a more specific and detailed examination compared to the PUTS, which can misinterpret sensory phenomena unrelated to tics as premonitory urges. In addition, because the I-PUTS is administered by the clinician, it is more suitable for patients who have high levels of anxiety or are distracted and inattentive.

Many tic disorder patients experience tics that arise from preceding premonitory urges, and most patients experience a reduction in premonitory urges after tic expression [3,15,16]. The reduction in premonitory urges after the manifestation of tics is a phenomenon of negative reinforcement [17,18]. In other words, a tic is not a completely involuntary movement but rather a semi-voluntary movement aimed to relieve the premonitory urges [12]. From these results, one can hypothesize that a premonitory urge of higher severity would induce more severe tics. However, outcomes from previous studies assessing the correlation between the severities of premonitory urges and tics were not consistent [8,9,13,19].

### Relationships between Premonitory Urges and Co-Occurring Psychiatric Disorders in Tourette’s Disorder

#### Obsessive compulsive disorder

Many obsessive compulsive disorder (OCD) patients exhibit repetitive actions after sensory phenomena such as premonitory urges, not after obsessive ideation; 65% of OCD patients were reported to experience at least one sensory phenomenon [20]. Also, patients with sensory phenomena had higher rates of comorbid tic disorders than those without sensory phenomena [20,21]. Another study demonstrated that the premonitory urge is associated with obsessive symptoms, and that the severity of the premonitory urge is directly proportional to the severity of obsessive symptoms [19,22]. More specifically, the group of patients with high PUTS scores showed high scores in symmetry, aggression, sexual, and religious dimensions on the Dimensional Yale-Brown Obsessive-Compulsive Scale [22].

Approximately 30–50% of TD patients have comorbid OCD [23]. TD patients with OCD exhibit repetitive, compulsive behavior until they experience a sense of completion [24]. During this process, TD patients are more susceptible to sensory inputs or sensory information such as premonitory urges compared to healthy individuals. If the patient continues to feel uncomfortable, the patient repetitively evaluates sensations including touch, seeing, or hearing. The “just right”
sensation, or a sense of “completeness,” is also sought [24-26]. Previous studies have reported that approximately 30–90% of TD patients experience this “just right” phenomenon [13,27-29].

Furthermore, the frequency of the “just right” phenomenon is higher in patients with both tic disorder and OCD compared to patients with only tic disorder or tic disorder with some obsessive-compulsive symptoms. The latter pertains to patients exhibiting subthreshold OCD symptoms not severe enough to merit a diagnosis with the actual disorder [10,12,13,30]. Based on these observations, premonitory urges can be considered to be compulsive thoughts. However, another study posited that the premonitory urge cannot be considered an obsessive symptom because patients with such urges do not manifest cognitive aspects of anxiety, i.e., the feeling that something bad might happen if the compulsive behavior is not performed. Premonitory urges are also limited to physical discomfort, unlike obsessive symptoms [11].

Anxiety disorders
Aversive experiences resulting from tics, such as pain during tics, bullying by peers, or attracting attention from others, are thought to be associated with premonitory urges [31]. If the patient does not perform tasks that he or she doesn’t want to do (i.e., homework or errands) because of tic symptoms, the onset or progression of premonitory urges will be affected [31-34]. In a study of adolescents aged 9 to 17 years old, Rozenman et al. [35] reported that the severity of anxiety and panic symptoms or somatic symptoms assessed using the Screen for Child Anxiety-Related Emotional Disorders-Child Version is associated with the PUTS score.

These results are in agreement with earlier studies that suggested an association between premonitory urges and psychological states (i.e., anxiety, mood symptoms, social withdrawal, and aggression) assessed using the Child Behavior Checklist (CBCL) [9]. However, these findings were limited to patients who were ≥11 years old and were not observed in patients ≤10 years old. These observations are once again in agreement with previous reports suggesting that pediatric patients who are 10 years or older can better recognize and report the symptoms of premonitory urges that they experience [3].

Attention-deficit/hyperactivity disorder
The most common comorbid psychiatric condition in TD patients is Attention-deficit hyperactivity disorder (ADHD). The rate of comorbidity is 40–60%, and developmentally, ADHD has an earlier onset compared to TD [36,37]. A previous neuroimaging study hypothesized that severe premonitory urges would cause a poorer attention span in ADHD patients [38]. The authors proposed that because tic suppression requires a high level of attention, the sensitive detection of premonitory urges is essential to suppress tics [38].

However, the association between ADHD symptoms and the severity of premonitory urges evaluated using the PUTS score was inconsistent. Reese et al. [8] reported no association between PUTS scores and ADHD rating scale (ARS) scores. Similarly, Steinberg et al. [19] and Woods et al. [9] also failed to identify any correlation between PUTS scores and ADHD symptoms evaluated using Conner’s ADHD rating scale. However, two studies in adult TD patients demonstrated an association between PUTS scores and ADHD symptoms evaluated using the Adult ADHD self-report scale [30,39].

Another study reported an association between behavioral problems such as aggression and premonitory urges. Woods et al. [9] confirmed a positive correlation between aggressive behavior assessed using the CBCL and premonitory urges assessed using the PUTS score in TD patients.

PREMONITORY URGE IN THE TREATMENT OF TOURETTE’S DISORDER
As stated above, the premonitory urge plays an important role in the manifestation of tic symptoms. A previous study demonstrated that 71% of TD patients believe that they would not have tics if their premonitory urges were no longer present [12]. The current behavioral treatment model is based on the theory that tic symptoms are abnormal movements produced to relieve the premonitory urges. This theory assists patients in understanding and treating their symptoms [40]. There are studies suggesting that pharmacological treatments, similar to behavioral treatments, can affect premonitory urges, as well as studies showing an association between premonitory urges and the treatment response rate and prognosis [24,41]. However, these findings require further elucidation.

Behavioral treatments
Behavioral treatment is one of the most effective treatment modalities, with a similar effect size and remarkably fewer side effects compared to pharmacological treatments (Table 1) [42]. Moreover, behavioral treatment becomes more effective as patients grow older and the treatment is administered for a sufficient length of time [42]. The best-studied behavioral treatments are Exposure and Response Prevention (ERP) and Habit Reversal Therapy (HRT), both of which significantly reduce tic symptoms [43]. Active tic suppression, the key mechanism of behavioral treatments, increases the activity of the left inferior frontal gyrus, which is responsible
for top-down motor control [44]. Baym et al. [45] reported a negative correlation between the severity of tic movement and top-down cognitive-motor control tasks.

ERP is one type of suppressive therapy used to prevent tics when the patient experiences premonitory urges. The mechanism by which ERP suppresses tics is most likely via habituation against the premonitory urge. The habituation mechanism allows a gradual reduction in the premonitory urge through the prolonged suppression of tics, although the temporary suppression of tics actually worsens premonitory urge [46]. Two previous studies observed a reduction in the premonitory urge using ERP [41,47]. However, another study showed contradictory results; the patient in this study did not exhibit a reduced premonitory urge despite continuous tic suppression [46].

HRT is a treatment modality that utilizes competing responses so that the patient does not exhibit tics when he or she feels the premonitory urge. HRT is also the core modality of Comprehensive Behavior Intervention for Tics (CBIT). The effectiveness of CBIT has been confirmed in multiple large-scale studies in pediatric and adult TD patients [48,49]. In adult TD patients, a relationship between CBIT and activation of the left inferior frontal gyrus of the brain has been suggested [50].

A recent study assessed the effectiveness of CBIT against premonitory urges [51]. The degree of reduction of premonitory urges was greater in the group that responded to CBIT compared to the group that did not. The authors demonstrated a reduction in the premonitory urge in adult patients; however, they did not observe this result in pediatric patients [51]. There was no difference between the group that responded to CBIT and the group that received supportive psychotherapy. Further, the authors could not conclude that the reduction in the premonitory urge led to the reduction in tic movements [51].

**Pharmacological treatments**

Very few studies have assessed the effect of pharmacological treatments on premonitory urges (Table 2). Treatment with botulinum toxin was effective not only against motor tics but also against vocal tics, and its effective reduction of premonitory urges should also be highlighted [52-55]. However, there are also studies reporting no changes in premonitory urges despite improvement of tic symptoms [56,57]. It is thus unclear whether or not botulinum toxin reduces premonitory urges and reduces tic symptoms as a result.

In a previous study, the selective dopamine receptor DR1 antagonist ecopipam was shown to be effective in relieving tic symptoms, but this agent did not reduce premonitory urges [58]. Another study on topiramate, which is known to act on

---

**Table 1. Studies about the effect of behavior therapy on premonitory urge severity**

| References         | Years | Participants | Method          | Control/comparison | Outcome                                                                 |
|--------------------|-------|--------------|-----------------|--------------------|------------------------------------------------------------------------|
| Hoogduin et al [47]| 1997  | 3 adults & 1 child with TD | ERP, 2-hours 10 sessions | ERP only            | 3 adults of the 4. PMU habituation both within & between sessions      |
| Himle et al [18]   | 2007  | 5 children & adolescents with TD or PTD | ERP, 5 consecutive, 5-min experimental trials | ERP only            | 4 of the 5 children demonstrated reliable suppression                 |
| Verdellen et al [41]| 2008| 19 adults & child with TD 15 males & 4 females | ERP, 2-hours 10 sessions | ERP only            | SUD score of 19 subjects, PMU habituation both within & between sessions |
| Specht et al [46]  | 2013  | 12 children & adolescents with TD or PTD | ERP, 10 min baseline control 3 sessions & 40 min tic suppression 2 sessions | Baseline control    | Urge ratings did not show the expected increase during the initial periods of tic suppression, nor a subsequent decline in urge ratings during prolonged, effective tic suppression |
| Houghton et al [51]| 2017  | 126 youths & 122 adults with TD | CBIT, 10 wks 8 sessions | PST                | Adults showed a significant trend of declining PMU severity, But results failed to demonstrate that HRT specifically caused changes in PMU severity. Children failed to show any significant changes in PMU severity |

CBIT: Comprehensive Behavioral Intervention for Tics, ERP: Exposure and Response Prevention, HRT: Habit Reversal Therapy, PMU: premonitory urge, PST: psychoeducation and supportive psychotherapy, PTD: persistent tic disorder, SUD: Subjective Units of Distress Scale, TD: Tourette’s disorder
Table 2. Studies about the effect of pharmacological treatments on PMU severity

| References     | Years | Participants | Medication (number) | Dose | Response of PMU | Complications (number or %) |
|----------------|-------|--------------|---------------------|------|-----------------|-----------------------------|
| Scott et al [53] | 1996  | A 13 year old boy | Botulinum toxin I.M. in vocal cord | 30 U | Decreased markedly | Hypophonia |
| Salloway et al [57] | 1996  | A 28 year old male | Botulinum toxin I.M. in vocal cord | Initial dose 1.25 U per side 3.75 U every 3 months | Not specified | Hypophonia |
| Trimble et al [56] | 1998  | A 34 year old male | Botulinum toxin I.M. in vocal cord | 3.75 mouse unit per side | Not specified | Hypophonia |
| Kwak et al [54] | 2000  | 30 males & 5 females (23.3±15.5 (8–69): year old | Botulinum toxin I.M. in cervical (17), upper face (14), lower face (7), vocal cord (4), other (3) | 119.9±70.1 U per visit total dose 502.1±779.4 U | Decreased markedly | Mild neck weakness (4) Transient ptosis (2) Mild dysphagia (2) Hypophonia (1) etc |
| Jankovic et al [59] | 2010  | 26 males & 3 females (16.5±9.88 (7–65): year old | Topiramate p.o. Titration depending on tolerance to 200 mg Mean dose 118 mg | YGTSS: 14.29±10.47 at baseline → 5.00±9.88 at visit 5 PMU CGI improved | Headache (3) Diarrhea (3) Abdominal pain (2) Drowsiness (2) etc |
| Gilbert et al [58] | 2014  | 15 males & 3 females 36.2 (18–63): year old | Ecopipam p.o. | 1–2 wks 50 mg daily 3–8 wks 100 mg daily | YGTSS: 30.6 at baseline → 25.3 at 8 wks there was no significant change in PMU | Sedation (39%) Fatigue (33%) Insomnia (33%) Somnolence (28%) etc |

CGI: Clinical Global Improvement. PMU: premonitory urge. YGTSS: Yale Global Tic Severity Scale

the GABA system or the glutamate receptor, showed that the drug effectively reduced both tic symptoms and premonitory urges in patients with TD [59]. However, very few studies have assessed the effects of commonly used drugs such as antipsychotic drugs and a2 agonists on the premonitory urge.

**CONCLUSION**

The premonitory urge is a type of sensory phenomenon preceding tic movements, and it may be the causal phenomenon that enables persistent tic movements. In addition, the premonitory urge is clinically significant because the majority of TD patients experience it. Previous studies have demonstrated that the premonitory urge is associated with anxiety, OCD, and ADHD. However, it is still unknown whether the severity of the premonitory urge is directly proportional to the severity of these comorbidities. Although behavioral and pharmacological treatments are available and are commonly used to treat TD, these therapies only partially reduce the premonitory urge and their effectiveness is inconsistent. Furthermore, the mechanisms of action of these treatments remain largely unknown. These findings indicate a complex correlation between the premonitory urge and tic movements. In summary, although treating patients with TD requires understanding the associations between the premonitory urge and tics or frequently occurring comorbid psychiatric conditions, these associations have not yet been clearly elucidated.

**Conflicts of Interest**

The authors have no potential conflicts of interest to disclose.

**REFERENCES**

1) Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998;102:14-19.
2) Rajagopal S, Seri And S, Cavanna AE. Premonitory urges and sensorimotor processing in Tourette syndrome. Behav Neurol 2013;27: 65-73.
3) Leckman JF, Walker DE, Cohen DJ. Premonitory urges in Tourette's syndrome. Am J Psychiatry 1993;150:98-102.
4) Montgomery M, Clayton P, Friedhoff A. Psychiatric illness in To-
urotelle syndrome patients and first-degree relatives. Adv Neurol 1982;35:335-339.
5) Shapiro AK, Shapiro ES, Young JG, Feinberg TE. Gilles de la Tourette syndrome. 2nd ed. England: Raven Press;1988.
6) Crossley E, Seri S, Stern JS, Robertson MM, Cavanna AE. Premonitory urges for tics in adult patients with Tourette syndrome. Brain Dev 2014;36:45-50.
7) Sutherland Owens AN, Miguel EC, Swerdlov NR. Sensory gating scales and premonitory urges in Tourette syndrome. Scientific WorldJournal 2011;11:736-741.
8) Reese HE, Scharll I, Peterson AL, Crowe K, Woods DW, Piccentini J, et al. The premonitory urge to tic: measurement, characteristics, and correlates in older adolescents and adults. Behav Ther 2014;45:177-186.
9) Woods DW, Piccentini J, Himle MB, Chang S. Premonitory urge for tics scale (PUTS): initial psychometric results and examination of the premonitory urge phenomenon in youths with tic disorders. J Dev Behav Pediatr 2005;26:397-403.
10) Sambrani T, Jakubovski E, Muller-Vahl KR. New insights into clinical characteristics of Gilles de la Tourette syndrome: findings in 1032 patients from a single German center. Front Neurosci 2016; 10:415.
11) Miguel EC, Coffey BJ, Baer L, Savage CR, Rauch SL, Jenike MA. Phenomenology of intentional repetitive behaviors in obsessive-compulsive disorder and Tourette’s disorder. J Clin Psychiatry 1995; 56:246-255.
12) Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord 2003;18:1530-1533.
13) Leckman JF, Walker DE, Goodman WK, Pauls DL, Cohen DJ. “Just right” perceptions associated with compulsive behavior in Tourette’s syndrome. Am J Psychiatry 1994;151:675-680.
14) McGuire JF, McBride N, Piccentini J, Johnco C, Lewin AB, Murphy TK, et al. The premonitory urge revisited: an individualized premonitory urge for tics scale. J Psychiatr Res 2016;83:176-183.
15) Brandt VC, Beck C, Sajin V, Baaske MK, Bäumer T, Beste C, et al. Temporal relationship between premonitory urges and tics in Gilles de la Tourette syndrome. Cortex 2016;77:24-37.
16) Seki K, Fetz EE. Gating of sensory input at spinal and cortical levels during preparation and execution of voluntary movement. J Neurosci 2012;32:890-902.
17) Capriotti MR, Brandt BC, Turkel JE, Lee HJ, Woods DW. Negative reinforcement and premonitory urges in youth with Tourette syndrome: an experimental evaluation. Behav Modif 2014;38:276-296.
18) Himle MB, Woods DW, Conelea CA, Bauer CC, Rice KA. Investigating the effects of tic suppression on premonitory urge ratings in children and adolescents with Tourette’s syndrome. Behav Res Ther 2007;45:2964-2976.
19) Steinberg T, Shmuel Baruch S, Harush A, Dar R, Woods D, Piccentini J, et al. Tic disorders and the premonitory urge. J Neural Transm (Vienna) 2010;117:277-284.
20) Ferrão YA, Shavitt RG, Prado H, Fontenelle LF, Malavazzi DM, De Matias MA, et al. Sensory phenomena associated with repetitive behaviors in obsessive-compulsive disorder: an exploratory study of 1001 patients. Psychiatry Res 2012;197:253-258.
21) Martino D, Madhusudan N, Zis P, Cavanna AE. An introduction to the clinical phenomenology of Tourette syndrome. Int Rev Neurobiol 2013;112:1-33.
22) Kano Y, Matsuda N, Nonaka M, Fuijio M, Kuwabara H, Kono T. Sensory phenomena related to tics, obsessive-compulsive symptoms, and global functioning in Tourette syndrome. Compr Psychiatry 2015;62:141-146.
23) Hounie AG, Do Rosario-Campos MC, Diniz JB, Shavitt RG, Ferrão YA, Lopes AC, et al. Obsessive-compulsive disorder in Tourette syndrome. Adv Neurol 2006;99:22-38.
24) Houghton DC, Capriotti MR, Conelea CA, Woods DW. Sensory phenomena in Tourette syndrome: their role in symptom formation and treatment. Curr Dev Disord Rep 2014;1:245-251.
25) Hetrick WP, Erickson MA, Smith DA. Phenomenological dimensions of sensory gating. Schizophr Bull 2010;38:178-191.
26) Taylor S, Conelea CA, McKay D, Crowe KB, Abramowitz JS. Sensory intolerance: latent structure and psychopathologic correlates. Compr Psychiatry 2014;55:1279-1284.
27) Miguel EC, Do Rosário-Campos MC, Prado HS, Do Valle R, Rauch SL, Coffey BJ, et al. Sensory phenomena in obsessive-compulsive disorder and Tourette’s disorder. J Clin Psychiatry 2000;61:150-156.
28) Neal M, Cavanna AE. “Not just right experiences” in patients with Tourette syndrome: complex motor tics or compulsions? Psychiatry Res 2013;210:559-563.
29) Worbe Y, Mallet L, Golmand JL, Béhar C, Durif F, Jalenques I, et al. Repetitive behaviours in patients with Gilles de la Tourette syndrome: tics, compulsions, or both? PLoS One 2010;5:e12959.
30) Eddy CM, Cavanna AE. Premonitory urges in adults with complicated and uncomplicated Tourette syndrome. Behav Modif 2014;38:264-275.
31) Capriotti MR, Espil FM, Conelea CA, Woods DW. Environmental factors as potential determinants of premonitory urge severity with Tourette syndrome. J Obsessive-Compuls Relat Disord 2013;2:37-42.
32) Capriotti MR, Piccentini JC, Himle MB, Ricketts EJ, Espil FM, Lee HJ, et al. Assessing environmental consequences of ticcing in youth with chronic tic disorders: the tic accommodation and reactions scale. Child Health Care 2015;44:205-220.
33) Zimmer SH, Conelea CA, Glew GM, Woods DW, Budman CL. Peer victimization in youth with Tourette syndrome and other chronic tic disorders. Child Psychiatry Hum Dev 2012;43:124-136.
34) Himle MB, Capriotti MR, Hayes LP, Ramanujam K, Scharll I, Sukhodolsky DG, et al. Variables associated with tic exacerbation in children with chronic tic disorders. Behav Modif 2014;38:163-183.
35) Rozenman M, Johnson OE, Chang SW, Woods DW, Walkup JT, Wilhelm S, et al. Relationships between premonitory urge and anxiety in youth with chronic tic disorders. Child Health Care 2015;44:235-248.
36) Leckman JF. Tourette’s syndrome. Lancet 2002;360:1577-1586.
37) Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564-577.
38) Peterson BS, Skudlarski P, Anderson AW, Zhang H, Gatenby JC, Lacadie CM, et al. A functional magnetic resonance imaging study of tic suppression in Tourette Syndrome. Arch Gen Psychiatry 1998; 55:326-333.
39) Crossley E, Cavanna AE. Sensory phenomena: clinical correlates and impact on quality of life in adult patients with Tourette syndrome. Psychiatry Res 2013;209:705-710.
40) Woods DW, Piccentini J, Chang S, Deckersbach T, Ginsburg G, Peterson A, et al. Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. 1st ed. New York: Oxford University Press;2008.
41) Verdellen CW, Hoogduin CA, Kato BS, Keijser GS, Cath DC, Hoijtkin HB. Habituation of premonitory sensations during exposure and response prevention treatment in Tourette’s syndrome. Behav Res Ther 2004;42:501-511.
42) Verdellen CW, Keijser GS, Cath DC, Hoogduin CA. Exposure with response prevention versus habit reversal in Tourette's syndrome: a controlled study. Behav Res Ther 2004;42:501-511.
45) Baym CL, Corbett BA, Wright SB, Bunge SA. Neural correlates of tic severity and cognitive control in children with Tourette syndrome. Brain 2008;131:165-179.
46) Specht MW, Woods DW, Nicotra CM, Kelly LM, Ricketts EJ, Conelea CA, et al. Effects of tic suppression: ability to suppress, rebound, negative reinforcement, and habituation to the premonitory urge. Behav Res Ther 2013;51:24-30.
47) Hoogduin K, Verdellen C, Cath D. Exposure and response prevention in the treatment of Gilles de la Tourette's syndrome: four case studies. Clin psychol psychother 1997;4:125-135.
48) Wilhelm S, Peterson AL, Piacentini J, Woods DW, Deckersbach T, Sukhodolsky DG, et al. Randomized trial of behavior therapy for adults with Tourette syndrome. Arch Gen Psychiatry 2012;69:795-803.
49) Piacentini J, Woods DW, Schall I, Wilhelm S, Peterson AL, Chang S, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA 2010;303:1929-1937.
50) Ganos C, Kahl U, Brandt V, Schunke O, Bäumer T, Thomalla G, et al. The neural correlates of tic inhibition in Gilles de la Tourette syndrome. Neuropsychologia 2014;65:297-301.
51) Houghton DC, Capriotti MR, Schall LD, Wilhelm S, Peterson AL, Walkup JT, et al. Investigating habituation to premonitory urges in behavior therapy for tic disorders. Behav Ther 2017;48:834-846.
52) Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994;9:347-349.
53) Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord 1996;11:431-433.
54) Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol 2000;57:1190-1193.
55) Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonetic tics in patients with Tourette’s syndrome using botulinum toxin type A. Neurol Sci 2004;24:420-423.
56) Trimble MR, Whurr R, Brookes G, Robertson MM. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 1998;13:617-619.
57) Salloway S, Stewart CF, Israeli L, Morales X, Rasmussen S, Blitzer A, et al. Botulinum toxin for refractory vocal tics. Mov Disord 1996;11:746-748.
58) Gilbert DL, Budman CL, Singer HS, Kurlan R, Chipkin RE. A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol 2014;37:26-30.
59) Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010;81:70-73.